Clinical Research Directory
Browse clinical research sites, groups, and studies.
Identification and Description of Patients With High-risk Non Metastatic RCC
Sponsor: University Hospital, Bordeaux
Summary
Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decisions
Official title: Identification and Description of Patients With High-risk Non Metastatic RCC (UroCCR 127)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
6109
Start Date
2026-04-17
Completion Date
2028-04-17
Last Updated
2026-08-07
Healthy Volunteers
No
Conditions
Interventions
Cohort 1
Overall RCC Population
Cohort 2
Non clear RCC population
Cohort 3
Clear RCC population stratified by eligibility based on the Keynote-564 study criteria
Locations (1)
CHU Bordeaux
Bordeaux, France